DelveInsight’s “Hypersomnia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Hypersomnia, historical and forecasted epidemiology as well as the Hypersomnia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Hypersomnia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Hypersomnia market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Hypersomnia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Hypersomnia market.
Request for a Free Sample Report @ Hypersomnia Market Forecast
Some facts of Hypersomnia Market Report are:
- Leading Hypersomnia companies working in the market are Merck, Theranexus, GlaxoSmithKline plc, BIOPROJET, Teva Pharmaceutical Industries, Drive DeVilbiss Healthcare LLC, Pfizer Inc, Avadel Pharmaceuticals Plc, Jazz Pharmaceuticals Inc, Takeda Pharmaceutical Company Limited, Other players.
- According to DelveInsight, Hypersomnia market size is expected to reach USD XX Million by2032.
- According to the Cigna Health and Life Insurance Company’s (CHLIC) April 2020 article, it was observed that the sale of sleep disorder prescriptions increased by 14.8% from February 16 to March 15 of the year compared to the same period in 2019. The surge in the development of pipeline drugs and the increase in lifestyle diseases, especially anxiety and depression, are expected to propel the growth of the market in the forecast period. However, the side effects of sleep disorder drugs are expected to limit the growth of the market.
- In July 2022, NLS pharma Ltd. reported that the European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP) has issued a positive opinion to grant Orphan Drug Designation (ODD) for Mazindol ER (Quilience) for the treatment of idiopathic hypersomnia (IH).
- In April 2022, Harmony Biosciences Holdings, Inc. initiated a Phase 3 trial evaluating the efficacy and safety of pitolisant in adult patients with idiopathic hypersomnia (IH), known as the INTUNE study.
Hypersomnia Overview
Hypersomnia is a sleep disorder that is recognized by prolonged nocturnal sleep periods occurring about three times per week. It is important for patients experiencing hypersomnia to lay down for short sleep breaks or naps during the daytime and sleep over 10 hours around evening time. Sometimes the naps might not provide relief to the patient suffering from hypersomnia and in turn, provide body ache that results in difficulty in moving. Some common symptoms of hypersomnia include slow speech, hallucinations, and loss of appetite.
Learn more about Hypersomnia, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/hypersomnia-market
Hypersomnia Market
The Hypersomnia market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Hypersomnia market trends by analyzing the impact of current Hypersomnia therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Hypersomnia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hypersomnia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Hypersomnia market in 7MM is expected to witness a major change in the study period 2019-2032.
Hypersomnia Market Drivers
- Increasing awareness about hypersomnia and its treatment options among people.
- The growing number of research and development activities for the development of new hypersomnia drugs.
- Rising demand for effective and safe medications for the treatment of hypersomnia.
- Increasing prevalence of sleep disorders due to changing lifestyle habits and growing stress levels in people’s lives.
Hypersomnia Epidemiology
The Hypersomnia epidemiology section provides insights into the historical and current Hypersomnia patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Hypersomnia market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Hypersomnia Epidemiology @ https://www.delveinsight.com/sample-request/hypersomnia-market
Hypersomnia Drugs Uptake
This section focuses on the uptake rate of the potential Hypersomnia drugs recently launched in the Hypersomnia market or expected to be launched in 2019-2032. The analysis covers the Hypersomnia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Hypersomnia Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Hypersomnia market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Hypersomnia Pipeline Development Activities
The Hypersomnia report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Hypersomnia key players involved in developing targeted therapeutics.
Request for a sample report to understand more about the Hypersomnia pipeline development activities @ https://www.delveinsight.com/sample-request/hypersomnia-market
Hypersomnia Therapeutics Assessment
Major key companies are working proactively in the Hypersomnia Therapeutics market to develop novel therapies which will drive the Hypersomnia treatment markets in the upcoming years are Merck, Theranexus, GlaxoSmithKline plc, BIOPROJET, Teva Pharmaceutical Industries, Drive DeVilbiss Healthcare LLC, Pfizer Inc, Avadel Pharmaceuticals Plc, Jazz Pharmaceuticals Inc, Takeda Pharmaceutical Company Limited, Other players.
Learn more about the emerging therapies & key companies @ https://www.delveinsight.com/sample-request/hypersomnia-market
Hypersomnia Report Key Insights
1. Hypersomnia Patient Population
2. Hypersomnia Market Size and Trends
3. Key Cross Competition in the Hypersomnia Market
4. Hypersomnia Market Dynamics (Key Drivers and Barriers)
5. Hypersomnia Market Opportunities
6. Hypersomnia Therapeutic Approaches
7. Hypersomnia Pipeline Analysis
8. Hypersomnia Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Hypersomnia Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Hypersomnia Competitive Intelligence Analysis
4. Hypersomnia Market Overview at a Glance
5. Hypersomnia Disease Background and Overview
6. Hypersomnia Patient Journey
7. Hypersomnia Epidemiology and Patient Population
8. Hypersomnia Treatment Algorithm, Current Treatment, and Medical Practices
9. Hypersomnia Unmet Needs
10. Key Endpoints of Hypersomnia Treatment
11. Hypersomnia Marketed Products
12. Hypersomnia Emerging Therapies
13. Hypersomnia Seven Major Market Analysis
14. Attribute Analysis
15. Hypersomnia Market Outlook (7 major markets)
16. Hypersomnia Access and Reimbursement Overview
17. KOL Views on the Hypersomnia Market
18. Hypersomnia Market Drivers
19. Hypersomnia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting